# A Study to Measure the Effect of Tolterodine Extended Release on the Thickness of the Bladder Wall in Patients With Overactive Bladder

> **NCT00137397** · PHASE4 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 80 (—)

## Conditions studied

- Urinary Incontinence

## Interventions

- **DRUG:** Tolterodine ER
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00137397
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** —
- **Final completion:** 2006-08
- **Target enrollment:** 80 (—)
- **Last updated:** 2021-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00137397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00137397, "A Study to Measure the Effect of Tolterodine Extended Release on the Thickness of the Bladder Wall in Patients With Overactive Bladder". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00137397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*